CA
LENZ

Clearstead Advisors’s LENZ Therapeutics LENZ Stock Holding History

Clearstead Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+1
New +$8 ﹤0.01% 3646

Other funds holding LENZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return

Clearstead Advisors's LENZ Position: Q2 2026 in Review

Clearstead Advisors opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #3646 among its holdings.

41 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Clearstead Advisors held 1 share of LENZ Therapeutics worth $6 as of Q2 2026.
  • LENZ Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • LENZ Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3646 holding.
  • 41 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.